ReviewOphthalmology and therapy2019
Reviewing the Pathophysiology Behind the Advances in the Management of Giant Cell Arteritis.
Review in Ophthalmology and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- European Headache Federation recommendations for neurologists managing giant cell arteritis.The journal of headache and pain · 2020Pooled it
- A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis.Arthritis research & therapy · 2023Trial
- Designing a workshop for a temporal artery biopsy simulation.Digital journal of ophthalmology : DJO · 2025Article
- Giant cell arteritis: reviewing the advancing diagnostics and management.Eye (London, England) · 2023Review
- Can a Giant Cell Arteritis (GCA) Risk Stratification Score Be Helpful in Clinical Practice?Cureus · 2022Article
- Giant Cell Arteritis: A Case-Based Narrative Review of the Literature.Current pain and headache reports · 2022Review
- An update on the clinical approach to giant cell arteritis.Clinical medicine (London, England) · 2022Article
- Monckeberg's Medial Sclerosis as a Cause for Headache and Facial Pain.Current pain and headache reports · 2021Review
- A new era for giant cell arteritis.Eye (London, England) · 2020Review
- Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Improving understanding of the underlying pathophysiology of giant cell arteritis (GCA) is transforming clinical management by identifying novel avenues for targeted therapies. One key area of concern for both clinicians and patients with GCA is glucocorticoid (GC) morbidity. The first randomised controlled trials of targeted treatment to reduce cumulative GC use in GCA have been published, with tocilizumab, an interleukin (IL)-6 receptor inhibitor, now the first ever licensed treatment for GCA. Further potential therapies are emerging owing to our enhanced understanding of the pathophysiology of the disease. Other improvements in the care of our patients are rapid access pathways and imaging techniques, such as ultrasound, which are becoming part of modern rheumatology practice in the UK, Europe and beyond. These have been highlighted in the literature to reduce delay in diagnosis and improve long-term outcomes for those investigated for GCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.